A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

Key Inclusion Criteria:

• Is a male or female ≥18 years of age;

• Has a current diagnosis of gastroparesis defined by the following:

1. Persistent gastrointestinal (GI) symptoms that, in the opinion of theInvestigator, are consistent with gastroparesis within 6 months prior toScreening; and

2. Documented delayed gastric emptying as determined by gastric emptying breathtest (GEBT) at Visit 2.

• Body mass index between 17 and 49 kg/m2, inclusive;

• If receiving treatment with a Food and Drug Administration (FDA)-approved andmarketed glucagon-like peptide-1 receptor agonist (GLP-1RA) for weight loss orreduce risk of major adverse cardiovascular events, and/or, receiving any otheragent(s) taken for weight loss, subjects may be considered for the study if ALL ofthe following criteria are satisfied:

1. Is not taking the agent(s) for the management of diabetes or blood glucose;

2. Has been on a stable dose of the agent(s) for at least 3 months beforeScreening and is expected to maintain the same dose throughout the study,including during GEBT;

3. Is tolerating the agent(s) well, according to the Investigator's judgment;

4. In the opinion of the Investigator, the study-qualifying signs/symptoms ofgastroparesis are NOT solely due to the the agent(s); and

5. Symptoms of gastroparesis were present before starting the agent(s).

Key Exclusion Criteria:

• Has a known primary cause of gastroparesis (eg, diabetes, surgery; acute, ongoing,or active viral illness; cancer, medications, musculoskeletal or connective tissuedisorders [eg, scleroderma, systemic lupus erythematosus], or other neurologicdisorder [eg, Parkinson's disease], postural orthostatic tachycardia syndrome (POTS), etc.]);

• Has a current diagnosis of Type 1 or Type 2 diabetes, according to the AmericanDiabetes Association. Pre-diabetes is not exclusionary;

• Has been hospitalized for gastroparesis or malnutrition within 3 months prior toScreening;

• Has a known or suspected GI mechanical obstruction (eg, peptic stricture) asdocumented by upper GI endoscopy, upper GI radiographic series, plain film abdomenX-ray, or computed tomography (CT) in the past 2 years prior to Randomization;

• Has a history of pyloric injection of botulinum toxin within 6 months of Screeningor planned injection(s) during the study;

• Has any history of pyloroplasty, pyloromyotomy, or gastric peroral endoscopicmyotomy (G-POEM) procedure;

• Has a history of gastric surgery;

• Has a history of or current diagnosis of intestinal malabsorption, recurrent orchronic pancreatitis, or other pancreatic exocrine disease;

• Has a history of severe and refractory constipation;

• Has a history or evidence of clinically significant arrhythmia;

• Currently receiving parenteral feeding or presence of a nasogastric or other gastricenteral tube (e.g. percutaneous endoscopic gastrostomy [PEG] or percutaneousendoscopic jejunostomy [PEJ] tube) for feeding or decompression; Note: patientsreceiving enteral feeding via a jejunostomy tube may be included if, in the opinionof the Investigator, the patient is also taking substantial oral solid intake andare not primarily dependent on enteral nutrition

• Has a substance use disorder or a positive alcohol or positive drug screen.